Drug Profile
Research programme: colorectal cancer therapeutics - AstraZeneca
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; Netherlands Cancer Institute
- Developer Agendia; AstraZeneca; Netherlands Cancer Institute
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Colorectal-cancer in USA
- 10 May 2011 Early research in Colorectal cancer in USA (unspecified route)